"The company's US based 100 per cent subsidiary company Zydus Pharmaceuticals (USA) Inc (Zydus) will begin informing on July 12, 2016 its customers that Zydus will start selling an authorized generic of Asacol HD (mesalamine delayed - release tablets 800 mg) in the US commencing on August 1, 2016," Cadila Helathcare said in a filing to the BSE.
Shares of Cadila Healthcare today closed at Rs 364.40 per scrip on BSE, up 1.26 per cent from its previous close.